B-cell response in solid organ transplantation

Stephanie G. Yi¹, Ahmed Osama Gaber² and Wenhao Chen¹

¹Division of Transplantation, Department of Surgery, Houston Methodist Hospital, Houston, TX, United States, ²Division of Transplant Immunology, Houston Methodist Research Institute, Houston Methodist Hospital, Houston, TX, United States

The transcriptional regulation of B-cell response to antigen stimulation is complex and involves an intricate network of dynamic signals from cytokines and transcription factors propagated from T-cell interaction. Long-term alloimmunity, in the setting of organ transplantation, is dependent on this B-cell response, which does not appear to be halted by current immunosuppressive regimens which are targeted at T cells. There is emerging evidence that shows that B cells have a diverse response to solid organ transplantation that extends beyond plasma cell antibody production. In this review, we discuss the mechanistic pathways of B-cell activation and differentiation as they relate to the transcriptional regulation of germinal center B cells, plasma cells, and memory B cells in the setting of solid organ transplantation.

KEYWORDS
B cells, alloimmunity, transcriptional (regulation), transplant, rejection

Introduction

Despite an overall improvement in 1-year graft survival (1), median kidney allograft survival is 94.3% at 1 year but decreases to 76.3% at 5 years (1, 2). Approximately 40% of kidney allografts fail in 10 years, and nearly 67% of failed allografts are due to T-cell-mediated (TCMR) and/or antibody-mediated rejection (ABMR) (3). Chronic ABMR has been identified as the leading cause of graft loss in kidney transplantation and appears minimally responsive to current immunosuppressive therapies (4). With inconclusive data from clinical trials (5–7), there is currently no standard of care for the treatment of chronic ABMR.

B cells play a key role in the long-term detrimental effect of alloimmune-mediated injury (8). In transplantation, B cells can produce donor-specific antibodies (DSAs). These antibodies promote acute and chronic rejection by activating complement which causes vascular injury and allograft loss. However, there are other effector mechanisms from antibody binding that contribute to allograft destruction. Human leukocyte antigen (HLA) (9) antibodies can have a direct effect on endothelial cell binding via Fc receptors on immune cells such as natural killer (NK) cells, macrophages, and neutrophils to
mediate allograft injury (10). This mechanism of inflammation occurs independently of traditional HLA-associated complement activation (11), hence explaining why complement inhibitors alone are not effective against AMR (12, 13). There are also anti-HLA antibodies that are directed toward alleles not found in the recipient (14). Increasing evidence suggests that these pathogenic antibodies can be directed at minor antigens and autoantigens in the transplanted allograft (14, 15).

The transcriptional regulation of B-cell response to antigen stimulation is complex and involves an intricate network of dynamic intra- and extracellular signals from cytokines and transcription factors. There is a strong interest in understanding B-cell immunobiology as it relates to antibody development and production in response to solid organ transplantation. B-cell contribution to alloimmunity ranges from plasma cell (PC) differentiation and maintenance of long-term humoral immunity, serving as antigen-presenting cells, organizing the formation of tertiary lymphoid organs, and secreting pro- and anti-inflammatory cytokines (16). In this review, we will provide a brief overview of B-cell development and differentiation, then discuss the mechanistic pathways of B-cell activation and differentiation, followed by a review of the transcriptional regulation of germinal center (GC) B cells, PCs, and memory B cells as they relate to solid organ transplant rejection.

Overview of B-cell development and differentiation

B-cell development starts as hematopoietic stem cells in the fetal liver at birth and continues in the bone marrow where stromal cells provide cytokines and chemokines to stimulate hematopoiesis (17). Known as “cellular niches,” these microenvironments control B-lymphocytic behavior within the bone marrow during development. The earliest precursors, pre–pro-B cells, require CXC chemokine ligand (CXCL) 12 produced by a small population of stromal cells (18). These stromal cells are scattered throughout the bone marrow and away from interleukin (IL)-7-secreting cells, which cause the maturation of B-cell precursors.

Prior to B-cell lymphopoiesis, hematopoietic stem cells differentiate into common lymphoid progenitor cells that express factors such as c-kit and IL-7Rα (19). Activation of these receptors causes expression of transcription factors E2A and early B-cell factor, which cause these progenitor cells to develop into pro-B cells (20). Pro-B cells in the bone marrow undergo V(D)J recombination, resulting in IgM-expressing immature B cells (21), which migrate to the spleen. These early B cells then become immunoglobulin (IgD)- and IgM-expressing mature B cells that are ready to be activated by foreign antigens (22).

Two signals are required for these mature B cells to differentiate into antibody-secreting PCs. The first signal is from antigen-coupled B-cell receptors and the second signal is from T-cell or non-T-cell-related antigens. T-cell-independent antigens, such as lipopolysaccharides and glycolipids, cause the differentiation of B cells into short-lived PCs that produce low-affinity antibodies (23). T-cell-dependent activation, via antigen stimulation and follicular helper T-cell (Thf) interaction, causes differentiation into short-lived PCs or cell entry into germinal centers (GCs) (24). It is in GCs where B cells evolve into high-affinity B-cell receptors (BCRs) via mutation and selection by CD4+ T cells (25). Here, B cells also develop memory in the form of long-lived PCs and memory B cells (26).

There are two important modulators of B-cell survival: B-cell-activating factors of the tumor necrosis factor (TNF) family (gene name TNFSF13b) (BAFF) and TNF ligand superfamily member 13 (APRIL) (27). Both ligands have three receptors, namely, TNF receptor superfamily member 13C [also known as BAFF receptor (BAFF-R) or BlyS receptor 3 (BR3)], TNF receptor superfamily member 17 [also known as B-cell maturation antigen (BCMA)], and TNF receptor superfamily member 13B [also known as transmembrane activator and cyclophilin ligand interactor (TACI)]. BAFF, also known as B-lymphocyte stimulator (BlyS) and TNF-APO-L-related leukocyte-expressed ligand (TALL-1), activates nuclear factor kappa B (NF-kB) signaling pathways upon interaction with BAFF-R. This trigger is important for B-cell survival as it signals the formation and maintenance of B cells (28). In the mouse model, overproduction of BAFF leads to autoimmune diseases like systemic lupus erythematosus (SLE) in humans (29), whereas gene deletion of BAFF prevents the development of an SLE-type disease (30). BAFF and APRIL are produced by myeloid cells, lymphoid cells, and toll-like receptor 9 (TLR9)-activated plasmacytoid dendritic cells and IL-2-activated natural killer cells (31). APRIL has been identified as being important in antibody class switching and plasma cell survival (32). Unlike BAFF, overproduction of APRIL in the animal model does not result in an SLE-type disease (33), but may be a target of interest for inhibiting SLE development in a mouse model (34).

The identification of these factors has led to the FDA-approved monoclonal antibody (mAb) belimumab, specific for BAFF (35), used to halt the immune response in SLE. Although belimumab has shown to have efficacy in reducing SLE disease (35, 36), belimumab has not shown the same results in kidney transplantation. In a double-blind, randomized, placebo-controlled phase 2 trial, Banham et al. observed that treatment with belimumab did not significantly reduce the number of naive B cells in 24 weeks (37). In the United States, studies are underway to further evaluate these findings.

Transcriptional regulation of germinal center B-cell formation

GCs are dynamic structures within peripheral lymphoid organs where T-cell-dependent B-cell selection occurs (38). Antigen-driven PCs and memory B cells from naive B cells
occur in secondary lymphoid tissue in B-cell follicles and in GCs in two phases (Figure 1) (39). Phase 1 starts when antigens attach to the BCR on naive B cells, which then process and present BCR-bound antigen on major histocompatibility complex (MHC) class II molecules (41). This results in short-lived PCs and GC B cells that form in B-cell follicles. These B cells migrate to the interfollicular border of the T- and B-cell zones, causing cell activation, proliferation, and long-term interactions with antigen-specific T cells (42). Most of these activated B cells enter phase 2, in which they differentiate into long-lived PCs and memory B cells in the GC. This B-cell access into the GC has been attributed to interclonal competition for T-cell-associated signals, which occurs outside the follicles (43) and prior to GC formation.

Tfh cells play a crucial role in GC formation and the regulation of GC B cells. Tfh cells are a distinct subset of antigen-activated CD4+ T cells that express chemokine receptor (CXCR) 5 and B-cell lymphoma 6 (BCL-6). CXCR5 is a central marker of Tfh cells and shown to be required by B cells for entry into follicles (44). BCL-6 is a transcriptional repressor and master regulator of Tfh cells and GC B cells (Figure 2). This key transcription factor is required for Tfh cell differentiation and is a potent antagonist of B-lymphocyte-induced maturation protein 1 (BLIMP1) (47). Specifically, BCL-6 works to silence PD-1 ligands in GC B cells by binding the promoter region of PD-L1 and intron of PD-L2 (48). GC precursor cells deficient in BCL-6 cannot migrate to the center of the follicle and become high-affinity, class-switched memory B cells and long-lived PCs (49). Additionally, a recent study in mice by Robinson et al. has suggested that the amount of BCL-6 in B cells shortly after antigen activation determines B-cell fate into and toward the GC (50).

It was commonly believed that the GC is also where immunoglobulin (Ig) class-switch recombination (CSR) occurs. CSR is an intrachromosomal DNA rearrangement of the Ig heavy chain locus, thus allowing mature B cells to express antibodies of IgA, IgG, or IgE classes without altering the specificity for the antigen. CSR relies on the activation of activation-induced cytidine deaminase (AID), uracil-DNA glycosylase (UNG), and apurinic-apyrimidinic endonuclease 1 (APE1) to target switch (S) regions (52). Activation-induced cytidine deaminase (AID) is essential for both somatic hypermutation (SHM) and CSR, and is expressed primarily in GCs (53). However, in a mouse model, Roco et al. showed that CSR is initiated over the first few days during the primary immune response (at the T-cell to B-cell interaction) and stops after B cells become GC cells and SHM starts (54). SHM is a major component of affinity maturation, in which the variable regions of the Ig gene produce high-affinity antibodies. The timeline of CSR suggests that CSR occurs outside the GC and

**FIGURE 1**

Germinal center response overview. The germinal center (GC) response consists of two phases (39). Phase 1 (A) involves the presentation of B-cell receptor (BCR)-bound antigens on major histocompatibility complex (MHC) class II T cells following antigen attachment and presentation to BCR on naive B cells. These B cells migrate to the interfollicular border of the T- and B-cell zones, causing cell activation, proliferation, and long-term interactions with antigen-specific T cells. Some of these B cells become short-lived plasma cells (PCs). Most of these activated B cells enter phase 2 (B), where they differentiate into long-lived PCs and memory B cells in the GC. B-cell access into the GC has been attributed to interclonal competition for T-cell-associated signals, which occurs outside the follicles and prior to GC formation. Adapted from Verstegen et al. (40) Figure created with BioRender.com.
restricting CSR in GC B cells potentially keeps a reservoir of more “naive-like” memory B cells. This is important as IgM+ memory B cells are considered more stable over time compared to that of class-switched memory B cells, and they can be rapidly activated in the setting of antigen interaction (infection or foreign pathogen) (55). These new discoveries may help us to understand the generation of pathogenic antibodies during allograft reaction (56).

Tfh cells exhibit seven distinction functions that affect B-cell activity: proliferation, survival, PC differentiation, SMH, CSR, adhesion, and attraction (44). Tfh cells express the CD40 ligand (CD40L) that provides a helper signal for maintaining B-cell survival, and produce IL-21 for promoting cell proliferation and differentiation. CD40L stimulation is a dominant mechanism for T-cell to B-cell interaction. T-cell-derived IL-4 and IL-21 cause transcriptional activation of signal transducer and activator of transcription (STAT) 6 and STAT4, which promote BCL-6 and BACH2, respectively, which interact with CCR4 on Tfh cells (63). This highlights higher-affinity GC B cells, resulting in affinity maturation. B cells without CCL22 and CCL17 receive less T-cell help and are unable to undergo affinity maturation. Similarly, Li

![Image of BCR activation](BioRender.com)
et al. showed that strong CD40 and BCR signals caused CBl degradation resulting in increased interferon regulatory factor (IRF) 4 expression and exit from GC affinity selection (64).

In disease processes with dysregulated GC reactions, such as B-cell lymphoma and autoimmune diseases, B cells with mutated BCRs have also been shown to enter the LZ and compete for antigen expression on follicular dendritic cells (65, 66). Those B cells with the highest affinity for the antigen can outcompete other B cells and present peptides on class II MHC. The cells can then receive positive selection signals when they interact with Tfh. However, the ability for BCR mutations to undergo affinity maturation is likely specific to the genetic signature of the disease process. Not all cells with BCR mutations go to the LZ. A recent study by Stewart et al. suggests that mutated BCRs are replaced following SHM, as they rarely reach the LZ (67). These mutated cells undergo apoptosis, whereas functional BCRs re-enter the cell cycle or migrate to the LZ. Additionally, in the murine model, IL-21 has shown to be important in not only sustaining the GC but also promoting the entry of antigen-specific LZ B cells into the cell cycle (68). In IL-21-deficient mice, there was a deficit of LZ B cells entering the S phase of the cell cycle. In the presence of IL-21, Tfh cell interaction with LZ B cells showed a transient expression of c-Myc, which appears necessary for centrosome proliferation (68). Gene expression analysis has shown that deficiency in c-Myc expression by Tfh cells leads to deregulation of DZ B-cell division and subsequent B-cell lymphoma (69). There are also lower-affinity B cells that do not undergo apoptosis and remain in the GC (62). These retained cells have been associated with aberrations in Fas and BCL-2, which are also seen in B-cell lymphoma (70).

There are several key factors associated with GC development. BCL-6 is key for the initiation of the GC reaction, including the downregulation of sphingosine-1-phosphate receptor type 1 (S1PR1) which otherwise helps mediate B-cell trafficking out of the follicle (9). Myocyte-specific enhancer factor (MEF2C) is required for GC formation, as it has a role in B-cell proliferation immediately after antigen stimulation (71). Interferon regulatory factors (47) are a family of transcription factors that play important roles in innate and adaptive immune responses, such as immune cell development and differentiation and pathogen response (72). Interferon regulatory factor 4 (IRF4) regulates myeloid cell development, thus playing an important role in regulating the inflammatory response. IRF4 has been found to both activate and repress BCL-6 transcription (73) and regulate Tfh cells (74). Early in GC formation, a transient and low expression of IRF4 leads to BCL-6 expression (75), while a more sustained and high level of IRF4 with BLIMP1 upregulates X-box binding protein 1 (XBP1), a transcription factor required for PC differentiation (73). In IRF4 knockout models, IRF4− B cells failed to differentiate into GC B cells (73). Additionally, BCL-6 has also been shown to increase complement activation required for positive selection in the murine model (76). As a transcriptional repressor, BCL-6 inhibits complement regulators thus allowing C3aR/C5aR signaling required for positive selection despite the presence of Tfh.

Overall, there are multiple distinct transcription factors that work in a complex but cohesive manner to activate or repress GC development. Understanding how GC development occurs is important in understanding how PC differentiation is regulated. This becomes especially pertinent when evaluating alloimmunity in the setting of chronic rejection in solid organ transplantation.

### Transcriptional regulation of plasma cell differentiation

Antibody production occurs in terminally differentiated B cells or PCs. Following GC exit, B cells either become memory cells or PCs (Figure 3). PC fate has been associated with the degree of antigen affinity (77). As mentioned previously, NF-κB pathways are activated by CD40 signals, inducing c-Myc or IRF4 expression. High sustained levels of IRF4 expression are required for PC differentiation (73). BLIMP1, the transcription repressor that can induce plasmablast differentiation, can also increase the level of IRF4 (78). High levels of IRF4 downregulate BCL-6 and induce BLIMP1 expression. Together, IRF4 and BLIMP1 repress the GC program and activate the PC differentiation program. STAT3 regulates PC differentiation by promoting cell survival through activation of such prosurvival genes as B-cell leukemia 2-like 1 (BLC2L1) and myeloid leukemia-1 (MCL1) (79). Conversely, IRF8 with PU.1 transcription factor inhibits GC B-cell differentiation to PCs (80). The balance between IRF4 and IRF8 may be crucial in determining B-cell fate (80).

There are several cytokines that appear to play important roles in B-cell proliferation. IL-21 is the most potent cytokine for stimulating PC differentiation and is key in B-cell proliferation (81). BTB domain and CNC homolog 2 (BACH2) and paired box 5 (PAX5) are upregulated in the light zone GC B cells. BACH2 appears to regulate light zone B cells to commit to the memory B-cell pathway by repressing of BCL-6 (45), as BACH2 deficiency leads to lower memory B-cell differentiation (82). Activated B-cell factor 1 (ABF-1) blocks the PC differentiation program (83). In the ABF-1-ER mouse model, ABF-1 promotes GC formation and memory B-cell differentiation. BCL-6 inhibits PC differentiation by repressing PR/SET domain 1 (PRDM1) expression (84). STAT5 appears to modulate BCL-6 expression, which then represses PRDM1 expression, thus promoting memory B-cell differentiation. When PRDM1 expression occurs, BLIMP1 is encoded, thus allowing for PC differentiation.

PC differentiation is also controlled by epigenetic programs. In an in-vivo T-cell-independent B-cell differentiation model, Scharer et al. described a cellular division-dependent cis-regulatory element (85). Enhancer of zeste 2 polycomb
repressive complex 2 (EZH2), a catalytic subunit of the polycomb complex, provides a repressive histone modification of H3K27m3 (trimethylation of histone H3 lysine 27) necessary for B-cell development during the GC reaction (86). Chemical inhibition of EZH2 resulted in enhanced PC formation ex vivo (85), as well as premature expression of BLIMP1. Barwick et al. showed that de-novo DNA methylation limits the regulation of PC differentiation by repressing the PC chromatin state (87).

PC generated during the GC reaction migrates to the bone marrow, where PCs can stay quiescent for a long duration of time. This may provide an important clue as to the chronic activation of the immune response during solid organ transplantation, despite immunosuppressive therapy.

**Allogenic B-cell response and transplant rejection**

Although alloreactive T cells are traditionally considered to be the primary culprit in mediating allograft reaction, it is the T- and B-cell interaction that plays a key role in generating humoral alloimmune responses so detrimental to the longevity of the solid organ transplant. As discussed previously, memory B cells are generated from low-affinity GC B cells in the light zone and will eventually enter the circulation as patrolling cells or stay in lymphoid or target organs. Solid organ allografts, such as in kidney transplantation, become ectopic lymphoid-like structures (88), where alloreactive B cells can form an extrafollicular response as short-lived PCs or return to B-cell follicles to initiate a GC reaction (89). In the GC, B cells can undergo SHM and compete for Tfh cell interactions for high antigen affinity. These B cells can then transition into long-lived PCs, while the lower affinity B cells remain as a more diverse pool of B cells (90). The lower affinity B cells can then circulate in their quiescent form until a recognizable antigen is encountered.

Follicular regulatory T (Tfr) cells are a unique subset of forkhead box P3 (FoxP3)+ regulatory T cells (Tregs) that inhibit Tfh and B cells. Tfr cells downregulate the co-stimulatory molecule cluster of differentiation 86 (91) (CD86) on B cells, producing inhibitory cytokines such as IL-10 (92). Like other
Tregs, Tfr cells can also express Helios, a marker reflecting enhanced immunosuppressive function (93). The balance between Tfr and Tfh is crucial for immune homeostasis and tolerance, as an aberrant Tfr/Tfh ratio has been linked to autoimmune diseases (94) such as systemic lupus erythematosus and myasthenia gravis (95). In kidney transplantation, antibody-mediated rejection has also been associated with an imbalance in circulating Tfr and Tfh cells (96).

As described previously, Tfh cells play an important role in alloreactivity and provide help to alloantigen-activated B cells. This is also evident in solid organ transplantation. Tfh cells are present in kidney transplant allografts with the pathological findings of T-cell-mediated rejection (97, 98). They can also stimulate alloantibody production, which mediates humoral responses against the transplanted organ (99). Tfr cells are found to be impaired in this setting, leading to an uncontrolled alloaggressive response from Tfh cells following transplantation. Similarly, Louis et al. observed a loss of regulatory T and B cells in kidney transplant recipient serum in the setting of ABMR (100). Similar to Treg cells, transitional B cells (Tfrb) play a role in immune suppression, as the authors found that Trb suppressed Tfh activation, Tfh- to B-cell activation, and antibody generation in vivo.

Immunosuppression has been found to alter the absolute number of Tfr and Tfh cells in kidney transplant recipients. Niu et al. showed that peripheral Tfr cells significantly decreased with calcineurin inhibitor-based therapy (101), while Tfh did not change. When transplant recipients were treated with alemtuzumab, a monoclonal antibody that binds CD52, there were lower numbers of total and subset Tfr cells and total Tfh cells, suggesting an impairment of the homeostatic proliferation of Tfr cells. Similarly, Maceo et al. showed a significant decrease in Tregs in peripheral blood mononuclear cells (PBMCs) of kidney transplant recipients compared to that of non-immunosuppressed healthy controls (102). Despite lymphodepletion, this shift to Tfh cells may result in increased memory B-cell formation and PCs, potentially increasing the risk of antibody-mediated rejection. Clinically, patients treated with alemtuzumab have been shown to have a higher incidence of chronic antibody-mediated rejection and donor-specific antibodies despite this antirejection therapy (103).

Another therapy being used on kidney transplant recipients is belatacept, a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) co-stimulatory inhibitor. Belatacept targets CD80/86 to prevent interaction with CD28 and CTLA-4, thus preventing the T- and B-cell interactions required for class-switch recombination and GC response. In early clinical trials, belatacept demonstrated a significant reduction in the incidence of DSA (104) but increased early rejection in this group (105, 106), suggesting the need for combination treatment. In non-human primate data, Schroder et al. showed feasibility of using co-stimulatory blockade via CTLA-4 Ig with plasma cell inhibition (via carfilzomib) for pretransplant desensitization and ABMR treatment (107, 108). The authors report that the selective targeting of CD28 reduced DSA, Tfh, and B-cell expansion while preserving Treg cells and promoting naive T and B cells. With strong evidence supporting the reduction of DSA using belatacept alone and with combination therapy, there are two ongoing clinical trials investigating the use of plasma cell inhibitors (carfilzomib (109) or daratumumab (110)) and belatacept for desensitization in patients awaiting kidney transplant.

Humoral immunity against the allograft may be due to a steady production of donor-specific antibodies created from alloreactive T- and B-cell interactions, despite immunosuppressive therapy. In mouse studies, B cells recognizing one specific donor MHC can receive stimulatory help from T cells specific to another donor MHC, thus stimulating alloantibodies against an allograft (111). When naïve CD4+ T cells were depleted by co-stimulation blockade of CD40/CD154, interferon-gamma (IFN-γ)-producing memory CD4+ T cells were still able to activate B cells (112). Thus, alloantibody response can be initiated prior to transplant due to the diverse repertoire in memory B cells (113). This may be undetectable in the serum, as donor-reactive memory B cells are not measured during immunologic risk assessments prior to transplant. Additionally, the failure of immunosuppressive therapy suggests that there is a heterogeneity of B-cell lymphocyte populations and functions.

Targeting memory B-cell longevity may be the answer to resolving immunosuppression failure in solid organ transplantation. In vaccine studies, B-cell-intrinsic autophagy has been shown to be critical for memory B-cell longevity (114) and maintenance (115). Chen et al. observed that autophagy was found to be essential for memory B-cell maintenance against viral infections in mice. The authors found decreased spontaneous cell death and increased B-cell survival in the presence of autophagy, as evidenced by increased FOXO1 and FOXO3 expression in memory B cells over time (115). In the absence of autophagy, there was increased oxidative stress and memory B-cell loss. FOXO3 silencing also led to a suppression of autophagy gene expression in memory B cells. In a subsequent study by Kodali et al., the authors demonstrated that in the presence of Nix- and Bnip3-mediated mitochondrial autophagy (116), there was maintenance of metabolic quiescence and longevity of memory B cells. In a transplant mouse model, Fribourg et al. showed the effect of autophagy in memory B cells in transplantation. By inhibiting autophagy through the chemical inhibitor 3-methyladenine, the authors demonstrated a decrease in DSA responses to alloantigens in treated versus control mice. Such important findings provide potential therapeutic targets against autophagy, which may help mitigate the B-cell response in clinical transplantation.

Summary

The intrinsic relationship between T- and B-cell pathways results in a complex interplay activating rejection pathways in solid organ transplantation. Transcriptional factors, such as IRF4, initially appear to affect allogenic T-cell effector
pathways (117), modulating the inflammatory response. Within this response, B-cell pathways become activated (118), creating a chronic pathway of rejection that is currently untreatable with current immunosuppressive therapies. Emerging evidence suggests that transcriptional regulation through B cells is the key to transplant tolerance. Elucidating various B-cell subtypes, like T-cell subtypes, may also be necessary to better understand early B-cell response on a transcriptional level. Future modalities investigating both metabolic and epigenetic regulation will prove useful in understanding the complexities within B-cell response in transplantation. Such information can provide important insights as to the early detection of immune risk prior to transplantation, specifically as it relates to B-cell response, as well as the development of therapeutic modalities for both prophylaxis and treatment against chronic allograft rejection.

**Author contributions**

SY and WC conceived and wrote the review. SY, AG, and WC contributed to the article and approved the submitted version.

**References**

1. Hart A, Lentine KL, Smith JM, Miller JM, Skews MA, Prentice M, et al. OPTN/SRTR 2019 annual data report: Kidney. Am J Transplant (2021) 21(52):21–137. doi: 10.1111/ajt.16502

2. Poggio ED, Augustine JJ, Arrigain S, Brennan DC, Schold JD. Long-term kidney transplantation graft survival-making progress when most needed. Am J Transplant (2021) 21(8):2824–32. doi: 10.1111/ajt.16463

3. Wekerle T, Segev D, Lechler R, Oberbauer R. Strategies for long-term preservation of kidney graft function. Lancet (2017) 389(10084):2152–62. doi: 10.1016/S0140-6736(17)31283-3

4. Bohmg GA, Eskandary F, Doberer K, Halloran PF. The therapeutic challenge of late antibody-mediated kidney allograft rejection. Transpl Int (2019) 32(8):775–88. doi: 10.1111/tri.13436

5. Eskandary F, Ilma B, Mühlbacher J, Wahrmann M, Regele H, Kozakowski N, et al. Anti-C1s monoclonal antibody BIVV009 in late antibody-mediated kidney allograft rejection-results from a first-in-patient phase I trial. Am J Transplant (2018) 18(4):916–26. doi: 10.1111/ajt.14528

6. Moreno F, Crespo M, Ruiz JC, Torres A, Gutierrez-Dalmau A, Osuna A, et al. Treatment of chronic antibody mediated rejection with intravenous immunoglobulins and rituximab: A multicenter, prospective, randomized, double-blind clinical trial. Am J Transplant (2018) 18(4):927–35. doi: 10.1111/ajt.14520

7. Eskandary F, Dürr M, Buddke K, Doberer K, Reinidl-Schwaighofer R, Wasser J, et al. ClaraKizumab in late antibody-mediated rejection: study protocol of a randomized controlled pilot trial. Trials (2019) 20(1):37. doi: 10.1186/s13063-018-3156-6

8. Gago M, Cornell LD, Kremers WK, Stegall MD, Cosio FG. Kidney allograft inflammation and fibrosis, causes and consequences. Am J Transplant (2012) 12(5):1199–207. doi: 10.1111/ajt.103911.x

9. Huang C, Gonzalez DG, Cote CM, Jiang Y, Hatzi K, Teater M, et al. The BCL6 RD2 domain governs commitment of activated B cells to form germinal centers. Cell Rep (2014) 8(5):1497–508. doi: 10.1016/j.celrep.2014.07.059

10. Jindra PT, Jin YP, Rosengurt E, Reed EF. HLA class I antibody-mediated endoedhelial cell proliferation via the mTOR pathway. J Immunol (2008) 180(4):2357–66. doi: 10.4049/jimmunol.180.4.2357

11. Valenzuela NM, McNamara JT, Reed EF. Antibody-mediated graft injury: complement-dependent and complement-independent mechanisms. Curr Opin Organ Transplant (2014) 19(1):33–40. doi: 10.1097/MOT.0000000000000404

12. Bentall A, Tyan DB, Sequeira F, Everly MJ, Gandhi MJ, Cornell LD, et al. Antibody-mediated rejection despite inhibition of terminal complement. Transpl Int (2014) 27(12):1235–43. doi: 10.1111/tri.12396

13. Burbach M, Saberielle C, Brochieriu I, Ridel C, Mesnard I, Dahan K, et al. Report of the ineffectiveness of eculizumab in two cases of severe antibody-mediated rejection of renal grafts. Transplantation (2014) 98(10):1056–9. doi: 10.1097/TP.0000000000000184

14. Valenzuela NM, Reed EF. Antibodies in transplantation: the effects of HLA and non-HLA antibody binding and mechanisms of injury. Methods Mol Biol (2013) 1034:1–70. doi: 10.1007/978-1-62703-493-7_2

15. Philogene MC, Jackson AM. Non-HLA antibodies in transplantation: when do they matter? Curr Opin Organ Transplant (2016) 21(4):427–32. doi: 10.1097/MOT.0000000000000355

16. Karahan GE, Claes FH, Heidt S. B cell immunity in solid organ transplantation. Front Immunol (2016) 7:686. doi: 10.3389/fimmu.2016.00686

17. Tokoyoda K, Egawa T, Sugiyama T, Choi BI, Nagasawa T. Cellular niches controlling B lymphocyte behavior within bone marrow during development. Immunity (2004) 20(6):707–18. doi: 10.1016/j.immuni.2004.05.001

18. Nagasawa T, Hirota S, Tachibana K, Takakura N, Nishikawa Kitamura S-i Y, et al. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBF/SDF-1. Nature (1996) 382(6592):635–8. doi: 10.1038/382635a0

19. Barata JT, Durum SK, Seddon B. Flip the coin: IL-7 and IL-7R in health and disease. Nat Immunol (2019) 20(12):1584–93. doi: 10.1038/s41590-019-0479-x

20. O’Riordan M, Grosschedl R. Coordinate regulation of B cell differentiation by the transcription factors EBF and E2A. Immunity (1999) 11(1):21–31. doi: 10.1016/S1074-7613(00)80078-3

21. Krangel MS. Gene segment selection in V(D)J recombination: accessibility and beyond. Nat Immunol (2003) 4(7):624–30. doi: 10.1038/ni0703-624

22. Chung JB, Silverman M, Monroe JG. Transitional B cells: step by step towards immune competence. Trends Immunol (2005) 26(6):343–9. doi: 10.1016/j.cellimm.2005.04.011

23. Hoffman W, Lakkis FG, Chalasani G. B cells, antibodies, and more. Clin J Am Soc Nephrol (2016) 11(1):137–54. doi: 10.2215/CJN.09430915

24. Nutt SL, Hodgkin PD, Tarlton DM, Corcoran LM. The generation of antibody-secreting plasma cells. Nat Rev Immunol (2015) 15(3):160–71. doi: 10.1038/nri3795

**Funding**

SY and WC were internally funded. SY was also funded by the Houston Methodist Hospital Clinical Scholars award.

**Conflict of interest**

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s note**

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
25. Kurosoki T, Kometani K, Ise W. Memory b cells. *Nat Rev Immunol* (2015) 15(3):149–58. doi:10.1038/nri3802

26. Meslin L, Ersching J, Victoria GD. Germline center b cell dynamics. *Immunity* (2016) 45(3):471–82. doi:10.1016/j.immuni.2016.09.001

27. Vincent FB, Morand EF, Schneider P, Mackay F. The BAFF/APRIL system in SLE pathogenesis. *Nat Rev Rheumatol* (2014) 10(6):365–73. doi:10.1038/ nrrheum.2014.111

28. Kreutzer M, Rauch M, Salter U, Birmelin J, Rizzi M, Grimbacher B, et al. Soluble BAFF levels inversely correlate with peripheral b cell numbers and the expression of BAFF receptors. *J Immunol* (2012) 188(1):497–503. doi:10.4049/ jimmunol.1103231

29. Mackay F, Woodcock SA, Lawton P, Ambrose C, Mackeider L, Schneider P, et al. Mice transgenic for BAFF develop lymphoproliferative disorders along with autoimmune manifestations. *J Exp Med* (1999) 190(11):1697–710. doi:10.1084/ jem.190.11.1697

30. Jacob CO, Prpic L, Puttermann C, Koss MN, Liu Y, Kollaros M, et al. Paucity of clinical disease despite serological autoimmunity and kidney pathology in lupus-prone new Zealand mixed 2328 mice deficient in BAFF. *J Immunol* (2006) 177(4):2671–80. doi:10.4049/jimmunol.177.4.2671

31. Vincent FB, Morand EF, Mackay F. BAFF and innate immunity: new therapeutic targets for systemic lupus erythematosus. *Immunol Cell Biol* (2009) 87(3):293–303. doi:10.1093/icb/icc111

32. Vincent FB, Saulee-Easton D, Figgett WA, Fairfax KA, Mackay F. The BAFF/APRIL system: emerging functions beyond b cell biology and autoimmunity. *Cytokine Growth Factor Rev* (2011) 22(3):203–15. doi:10.1016/j.cytogfr.2011.04.003

33. Mackay F, Schneider P. Cracking the BAFF code. *J Immunol* (2009) 183(9):491–502. doi:10.4049/jimmunol2572

34. Huard B, Tran NL, Benkhoucha M, Manzin-Lorenzi C, Santiago-Raber ML. Selective APRIL blockade delays systemic lupus erythematosus in mice. *PloS One* (2012) 7(2):e31837. doi:10.1371/journal.pone.0031837

35. Navarre SV, Guzman RM, Gallacher AE, Hall S, Lery RA, Jimeiner RE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. *Lancet* (2011) 377(9767):271–31. doi:10.1016/S0140-6736(10)63542-9

36. Farrie R, Petri M, Zama N, A phase III, randomised, placebo-controlled study of belimumab as a monochlonal antibody that inhibits b lymphocyte stimulator, in patients with systemic lupus erythematosus. *Arthritis Rheumatism*. (2011) 63(12):3918–30. doi:10.1002/art.30613

37. Banham GD, Flinn SM, Torpey N, Lyons PA, Shahanah DN, Gibson A, et al. Belimumab in kidney transplantation: an experimental medicine, randomised, placebo-controlled phase 2 trial. *Lancet* (2018) 391(10140):2619–30. doi:10.1016/S0140-6736(18)30984-X

38. Klein U, Dalla-Favera R. Germline centers: role in b-cell physiology and malignancy. *Nat Rev Immunol* (2008) 8(1):22–33. doi:10.1038/nri2217

39. Avalos A, Ploegh H. Early BCR events and antigen capture, processing, and loading on MHC class II on b cells. *Front Immunol* (2014) 5. doi:10.3389/ fimmu.2014.00092

40. Verstegen NJM, Ubel S, Westerhof HV, van Ham SM, Barberis M, et al. System-level scenarios for the elucidation of T cell-mediated germinal center b cell differentiation. Front Immunol (2021) 12. doi:10.3389/fimmu.2021.634035

41. Hernandez-Perez S, Vaino M, Kuokkanen E, Saito M, Mackay F, et al. The proto-oncogene MYC is required for selection in the germinal center. *J Immunol* (2012) 188(11):5025–32. doi:10.4049/jimmunol.1200524

42. Olaka T, Miller MJ, Park R, Krummel MF, Neighbors M, Hartford SL, et al. B cells rapidly target antigen and surface-derived MHCII into peripheral degradative compartments. *Cell* (2019) 133(5):e235192. doi:10.1016/j. cell.2019.115758

43. Schwickert TA, Victora GD, Fooksman DR, Kamphorst AO, Mugnier MR, et al. Dynamic T cell–limited checkpoint regulates affinity-dependent b cell entry into the germinal center. *J Exp Med* (2011) 208(6):1243–52. doi:10.1084/ jem.20102477

44. De Silva NS, Klein U. Dynamics of b cells in germinal centres. *Nat Rev Immunol* (2015) 15(3):137–48. doi:10.1038/nri3804

45. Lahnmann A, Kuhrau J, Fuhrmann F, et al. Bach2 controls T follicular helper cell entry into the germinal center. *J Exp Med* (2011) 208(6):1243–52. doi:10.1084/ jem.20102477

46. De Silva NS, Klein U. Dynamics of b cells in germinal centres. *Nat Rev Immunol* (2015) 15(3):137–48. doi:10.1038/nri3804

47. Lahnmann A, Kuhrau J, Fuhrmann F, et al. Bach2 controls T follicular helper cell entry by direct repression of bcl-6. *J Immunol* (2019) 202(11):2239–39. doi:10.4049/ jimmunol.1901400

48. Song S, Matthias PD. The transcriptional regulation of germinal center formation. *Front Immunol* (2018) 9. doi:10.3389/fimmu.2018.00206

49. Nutt SL, Fairfax KA, Kalles A. BLIMP1 guides the fate of effector b and T cells. *Nat Rev Immunol* (2007) 7(12):923–7. doi:10.1038/nri2020

50. Peng C, Hu Q, Yang F, Zhang H, Li F, Huang C. BCL6-mediated silencing of PD-1 ligands in germinal center b cells maintains follicular T cell population. *J Immunol* (2019) 202(7):2024–13. doi:10.4049/jimmunol.1800876
70. Razzazhi R, Agarvar S, Kotlov N, Piotrikova O, Nomie K, Huang DW, et al. Compromised counterselection by FAS creates an aggressive subtype of germinal center lymphoma. J Exp Med (2021) 218(3).

71. Wilker PR, Kobayama M, Sandau MM, Albring JC, Nakagawa O, Schwarz JJ, et al. Transcription factor Meis2 is required for b cell proliferation and survival after antigen receptor stimulation. Nat Immunol (2008) 9(6):603–12. doi: 10.1038/nim.2008.2.

72. Tamura T, Carbone RA, Savitsky O, Taniguchi T. The IRF family transcription factors in immunity and oncogenesis. Annu Rev Immunol (2008) 26:535–84. doi: 10.1146/annurev.immunol.26.021607.094000.

73. Ochiai K, Mainscheins-Chine M, Simonetti G, Chen J, Rosenthal R, Brink R, et al. Transcriptional regulation of germinal center b and plasma cell fates by dynamic control of IRF4. Immunity (2013) 38(5):918–29. doi: 10.1016/j.immuni.2013.04.009.

74. Bolling N, Brustle A, Kellner K, Ackermann W, Absa E, Raifer H, et al. Transcription factor IRF4 determines germinal center formation through follicular T helper cell differentiation. Proc Natl Acad Sci U S A (2010) 107(22):9664–9. doi: 10.1073/pnas.1005834109.

75. Sciammas R, Li Y, Warmflash A, Song Y, Dinner AR, Singh H. An incoherent regulatory network architecture that orchestrates b cell diversification in response to antigen signaling. Mol Syst Biol (2011) 7:495. doi: 10.1038/msb.2011.25.

76. Cumpelik A, Heja D, Hu Y, Varano G, Ordikhani F, Roberto MP, et al. Dynamic regulation of b cell complement signaling is integral to germinal center responses. Immunity (2011) 34(2):157–67. doi: 10.1016/j.immuni.2011.05.006.

77. Ise W, Kurowski T. Plasma cell differentiation during the germinal center reaction. Immunol Rev (2019) 288(1):64–74. doi: 10.1111/ir.12751.

78. Minnich M, Tagoh H, Böntel P, Axelsson E, Fischer M, Cebolla B, et al. Multifunctional role of the transcription factor blimp-1 in coordinating plasma cell differentiation. J Exp Med (2014) 211(11):2169–81. doi: 10.1084/jem.20140425.

79. Kim SJ, Caton M, Wang C, Khalil M, Zhou ZJ, Hardin J, et al. Increased IL-79. Ding C, Chen X, Dascani P, Hu X, Bolli R, Zhang H-g, et al. STAT3 signaling in b cells is critical for germinal center maintenance and contributes to the pathogenesis of murine lupus. J Immunol (2016) 196(11):4477–86. doi: 10.4049/jimmunol.1502043.

80. Carota S, Willis SN, Hashold J, Inouye M, Pang SHM, Emilie D, et al. The transcription factors IRF8 and PU. 1 negatively regulate plasma cell differentiation. The control of plasma cell differentiation. J Exp Med (2014) 211(1):235–48. doi: 10.1084/jem.20070731.

81. Shimanao K, Inoue T, Komatsui K, Moriyama S, Adachi Y, Nakayama M, et al. Regulated selection of germinal-center cells into the memory b cell compartment. Nat Immunol (2016) 17(7):861–9. doi: 10.1038/ni.3460.

82. Chu Y-K, Lin Y, Su S-T, Wang K-H, Yang S-Y, Tsai D-Y, et al. Transcription factor ARF-I suppresses plasma cell differentiation but facilitates memory b cell formation. J Immunol (2014) 193(5):2207–17. doi: 10.4049/jimmunol.1400411.

83. Scheeren FA, Naspetti M, Schotte R, Nagasawa M, Wijnands E, Ahmed A, Song Y, Dinner AR, Singh H. An ectopic lymphoid structure in infection, cancer and autoimmunity.

84. Scharer CD, Barwick BG, Guo M, Bally APR, Boss JM. Plasma cell differentiation is controlled by multiple cell division-coupled epigenetic programs.

85. Scharer CD, Barwick BG, Martinez RJ, Price MJ, Wein AN, Haines RR, et al. Preoperative cell cycle analysis predicts a positive effect of belatacept and long-term outcomes in kidney transplantation. Transplant Proc (2012) 44(10):3405–7. doi: 10.1016/j.transproceed.2014.08.037.

86. Barwick BG, Scharer CD, Martinez RJ, Price MJ, Wein AN, Haines RR, et al. Conversion of calcineurin inhibitor– to belatacept-based maintenance immunosuppression in renal transplant recipients: A randomized phase 3b trial. J Am Soc Nephrol (2021) 32(12):3525–64. doi: 10.1681/ASN.20201505628.

87. Vincenti F, Rostaing L, Grinyo J, Rice K, Steinberg S, Gaite L, et al. Belatacept and long-term outcomes in kidney transplantation. N Engl J Med (2016) 374(4):333–43. doi: 10.1056/NEJMoa1508027.

88. Vincenti F, Charpentier B, Vanrenterghem Y, Rostaing L, Bresnahan B, Darzi P, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BEENEFIT study). Am J Transplant (2010) 10(3):535–46. doi: 10.1111/j.1600-6143.2009.03005.x.

89. Schroder SM, Schmitz R, Fitch ZW, Ezekian B, Yoon J, Choi AY, et al. Preoperative carfilzomib and bortezomib based desensitization prolongs graft survival in a sensitized non-human primate model. Kidney Int (2021) 99(1):161–72. doi: 10.1016/j.kint.2020.08.020.

90. Ezekian B, Schroder SM, Mulvihill MS, Barnes A, Collins B, Freischlag K, et al. Pretransplant desensitization with costimulatory blockade and proteasome inhibitor reduces DSA and delays antibody-mediated rejection in highly sensitized nonhuman primate kidney transplant recipients. J Am Soc Nephrol (2019) 30(12):2399–411. doi: 10.1681/ASN.2019030304.

91. Carfilzomib and belatacept for desensitization. Available at: https://ClinicalTrials.gov/CT00517545.

92. Daratumumab and belatacept for desensitization. Available at: https://ClinicalTrials.gov/CT00487979.

93. Conlon TM, Cole JL, Motallebehazdeh B, Harper I, Callaghan CJ, Bolton EM, et al. Unlinked memory helper responses promote long-lasting humoral alloimmunity. J Immunol (2012) 189(12):5703–11. doi: 10.4049/jimmunol.1202257.

94. Gorbacheva V, Fan R, Wang X, Baldwin WM3rd, Fairchild RL, Valujskikh A. IFN-γ production by memory helper T cells is required for CD40-independent alloantibody responses. J Immunol (2015) 194(3):1347–56. doi: 10.4049/jimmunol.1401573.
113. Lavinder JJ, Horton AP, Georgiou G, Ippolito GC. Next-generation sequencing and protein mass spectrometry for the comprehensive analysis of human cellular and serum antibody repertoires. *Curr Opin Chem Biol* (2015) 24:112–20. doi: 10.1016/j.cbpa.2014.11.007

114. Chen M, Hong MJ, Sun H, Wang L, Shi X, Gilbert BE, et al. Essential role for autophagy in the maintenance of immunological memory against influenza infection. *Nat Med* (2014) 20(5):503–10. doi: 10.1038/nm.3521

115. Chen M, Kodali S, Jang A, Kuai L, Wang J. Requirement for autophagy in the long-term persistence but not initial formation of memory b cells. *J Immunol* (2015) 194(6):2607–15. doi: 10.4049/jimmunol.1403001

116. Kodali S, Li M, Budai MM, Chen M, Wang J. Protection of quiescence and longevity of IgG memory b cells by mitochondrial autophagy. *J Immunol* (2022) 208(5):1085–98. doi: 10.4049/jimmunol.2100969

117. Wu J, Zhang H, Shi X, Xiao X, Fan Y, Minze LJ, et al. Ablation of transcription factor IRF4 promotes transplant acceptance by driving allogenic CD4(+) T cell dysfunction. *Immunity* (2017) 47(6):1114–1128.e1116. doi: 10.1016/j.immuni.2017.11.003

118. Wang G, Zou D, Wang Y, Gonzalez NM, Yi SG, Li XC, et al. IRF4 ablation in b cells abrogates allogenic b cell responses and prevents chronic transplant rejection. *J Heart Lung Transplant* (2021) 40(10):1122–32. doi: 10.1016/j.healun.2021.06.008
## Glossary

| Abbreviation | Description |
|--------------|-------------|
| ABF-1        | activated B-cell factor 1 |
| AID          | activation-induced cytidine deaminase |
| ABMR         | antibody-mediated rejection |
| APE1         | apurinic-apyrimidinic endonuclease 1 |
| c-Myc        | avian myelocytomatosis virus oncogene cellular homolog |
| BAFF         | B-cell activation factor of the TNF family |
| BCL-6        | B-cell lymphoma 6 |
| BCL2LC1      | B-cell leukemia 2-like 1 |
| BCMA         | B-cell maturation antigen |
| BCR          | B-cell receptor |
| BCRP         | B-cell receptor protein |
| BLIMP1       | B-lymphocyte-induced maturation protein 1 |
| BR3          | BlyS receptor 3 |
| BACH2        | BTB domain and CNC homolog 2 |
| CCL22        | C-C motif chemokine ligand 22 |
| CCL17        | C-C motif chemokine ligand 17 |
| CD40L        | CD40 ligand |
| CXCR         | chemokine receptor |
| CD           | cluster of differentiation |
| CXCL         | CXC chemokine ligand |
| CTLA-4       | cytotoxic T-lymphocyte-associated antigen 4 |
| DZ           | dark zone |
| DSAs         | donor-specific antibodies |
| EZH2         | enhancer of zeste 2 polycomb repressive complex 2 |
| Trb          | follicular helper T cells |
| Tfr          | follicular regulatory T cells |
| FOXO1        | forkhead box protein O1 |
| FOXO3        | forkhead box protein O3 |
| FoxP3        | forkhead box P3 |
| GC           | germinal center |
| HLA          | human leukocyte antigen |
| Ig           | immunoglobulin |
| IFN-γ        | interferon-gamma |
| IRF          | interferon regulatory factor |
| IL           | interleukin |
| LZ           | light zone |
| MHC          | major histocompatibility complex |
| mAb          | monoclonal antibody |
| MCL-1        | myeloid cell leukemia-1 |
| MEF2C        | myocyte-specific enhancer factor |
| NK           | natural killer |
| NF-κB        | nuclear factor kappa B |
| PAX5         | paired box 5 |
| PBMCs        | peripheral blood mononuclear cells |
| PCs          | plasma cells |
| PRDM1        | PR/SET domain 1 |
| STAT         | signal transducer and activator of transcription |

(Continued)